1. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4): 271-289.
2. Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009; 113(9): 2014-2021.
3. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 2007; 110(6): 2057-2066.
4. Angrand PO, Vennin C, Le Bourhis X, Adriaenssens E. The role of long non-coding RNAs in genome formatting and expression. Front Genet. 2015; 6: 165.
5. Bhan A, Soleimani M,Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017; 77(15): 3965-3981.
6. Ernst C, Morton CC. Identification and function of long non-coding RNA. Front Cell Neurosci. 2013; 7: 168.
7. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018; 172(3): 393-407.
8. Raveh E, Matouk IJ, Gilon M, Hochberg A. The H19 Long noncoding RNA in cancer initiation, progression and metastasis–a proposed unifying theory. Mol Cancer. 2015; 14(1): 184.
9. Yoshimura H, Matsuda Y, Yamamoto M, Kamiya S, Ishiwata T. Expression and role of long non-coding RNA H19 in carcinogenesis. Front Biosci (Landmark Ed). 2018; 23: 614-625.
10. Zhang EB, Han L, Yin DD, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. Med Oncol. 2014; 31(5): 914.
11. Yoshimura H, Matsuda Y, Suzuki T, Naito Z,Ishiwata T. Long noncoding RNA H19 as a novel therapeutic target for pancreatic cancer. Cancer Res. 2014; 74 Suppl 19: 5203.
12. Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019; 8(9): 1015.
13. Li Y, Ma HY, Hu XW, Qu YY, Wen X, Zhang Y, et al. LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. Cancer Cell Int. 2020; 20: 200.
14. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018; 18(1): 5-18.
15. Yoshimizu T, Miroglio A, Ripoche MA, Gabory A, Vernucci M, Riccio A, et al. The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci USA. 2008; 105(34): 12417-12422.
16. Cerk S, Schwarzenbacher D, Adiprasito JB, Stotz M, Hutterer GC, Gerger A, et al. Current status of long non-coding RNAs in human breast cancer. Int J Mol Sci. 2016; 17(9): 1485.
17. Lottin S, Adriaenssens E, Dupressoir T, Berteaux N, Montpellier C, Coll J, et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis. 2002; 23(11): 1885-1895.
18. Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2013; 26(2): 155-165.
19. Tanos V, Ariel I, Prus D, De-Groot N, Hochberg A. H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. Int J Gynecol Cancer. 2004; 14(3): 521-525.
20. Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L, et al. High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS lett. 2014; 588(9): 1780-1786.
21. Morlando M, Ballarino M, Fatica A. Long non-coding RNAs: new players in hematopoiesis and leukemia. Front Med (Lausanne). 2015; 2: 23.
22. Zhang Tj, Zhou Jd, Zhang W, Lin J, Ma Jc, Wen Xm, et al. H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia. Clin Epigenetics. 2018; 10(1): 47.
23. Lim YW, Xiang X, Garg M, Le MT, Wong A L-A, Wang L, et al. The double-edged sword of H19 lncRNA: Insights into cancer therapy. Cancer Lett. 2021; 500: 253-262.
24. Arun G, Diermeier SD,Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018; 24(3): 257-277.
25. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One. 2007; 2(9): e845.
26. Huang J, Zhang A, Ho TT, Zhang Z, Zhou N, Ding X, et al. Linc- RoR promotes c-Myc expression through hnRNP I and AUF1. Nucleic Acids Res. 2016; 44(7): 3059-3069.
27. Li Y, Sasaki H. Genomic imprinting in mammals: its life cycle, molecular mechanisms and reprogramming. Cell Res. 2011; 21(3): 466-473.
28. Dugimont T, Montpellier C, Adriaenssens E, Lottin S, Dumont L, Iotsova V, et al. The H19 TATA-less promoter is efficiently repressed by wild-type tumor suppressor gene product p53. Oncogene. 1998; 16(18): 2395-2401.
29. Liu C, Chen Z, Fang J, Xu A, Zhang W, Wang Z. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumour Biol. 2016; 37(1): 263-270.
30. Park IY, Sohn BH, Choo JH, Joe CO, Seong JK, Lee YI, et al. Deregulation of DNA methyltransferases and loss of parental methylation at the insulin-like growth factor II (Igf2)/H19 loci in p53 knockout mice prior to tumor development. J Cell Biochem. 2005; 94(3): 585-596.
31. Petit C, Gouel F, Dubus I, Heuclin C, Roget K,Vannier J. Hypoxia promotes chemoresistance in acute lymphoblastic leukemia celllines by modulating death signaling pathways. BMC Cancer. 2016; 16(1): 746.
32. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011; 11(6): 393-410.
33. Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, et al. Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012; 13(10): 858-870.
34. Luo M, Li Z, Wang W, Zeng Y, Liu Z, Qiu J. Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. FEBS J. 2013; 280(7): 1709-1716.
35. Matouk IJ, Mezan S, Mizrahi A, Ohana P, Abu-lail R, Fellig Y, et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta. 2010; 1803(4): 443-451.
36. Fahy L, Calvo J, Chabi S, Renou L, Le Maout C, Poglio S, et al. Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop. Blood Adv. 2021; 5(2): 513-526.
37. Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012; 279(17): 3159-3165.
38. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, et al. Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2011; 57(3): 443-453.
39. Deynoux M, Sunter N, Hérault O, Mazurier F. Hypoxia and hypoxiainducible factors in leukemias. Front Oncol. 2016; 6: 41.